Erik van den Berg
Amministratore Delegato presso AM-Pharma Holding BV
Provenienza dei contatti di primo grado di Erik van den Berg
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Biotechnology | 20 | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.
16
| Holding Company | Biotechnology | 16 |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France.
12
| Holding Company | Pharmaceuticals: Major | 12 |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands.
12
| Subsidiary | Pharmaceuticals: Major | 12 |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff.
6
| Holding Company | Miscellaneous Commercial Services | 6 |
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland.
6
| Holding Company | Biotechnology | 6 |
Lead Pharma Holding BV
 Lead Pharma Holding BV Pharmaceuticals: MajorHealth Technology Lead Pharma Holding BV develops small-molecule drugs for the treatment of autoimmune diseases and cancer. It specializes in medicinal, computational, and protein chemistry, x-ray crystallography, cell biology, and integration x-omics. The company was founded by Ad van Gorp, Leon de Windt, and Pieter Doevendans in 2007 and is headquartered in Oss , the Netherlands.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Erik van den Berg tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member Chairman Director/Board Member Director/Board Member | |
| University of Amsterdam | College/University | Undergraduate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Kurma Partners SA
 Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France. | Investment Managers | Corporate Officer/Principal Private Equity Investor Private Equity Investor | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Doctorate Degree Graduate Degree | |
| University of Leiden | College/University | Doctorate Degree Doctorate Degree Graduate Degree | |
| MEDIGENE AG | Biotechnology | Director/Board Member Chief Executive Officer Corporate Officer/Principal | |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Director/Board Member Chief Executive Officer | |
| Columbia Business School | College/University | Masters Business Admin Masters Business Admin | |
EQT Life Sciences Group BV
 EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor | |
Andera Partners SCA
 Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Investment Managers | Private Equity Investor Private Equity Investor | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Arvelle Therapeutics International GmbH
 Arvelle Therapeutics International GmbH BiotechnologyHealth Technology Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Founder | |
| University of Oxford | College/University | Graduate Degree Undergraduate Degree | |
| INTEGRAGEN | Medical/Nursing Services | Director/Board Member Director/Board Member | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
| IMPLANET SA | Medical Specialties | Director/Board Member Director/Board Member | |
| POXEL | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Domain Therapeutics SA
 Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Biotechnology | Director/Board Member Director/Board Member | |
Biospace Lab SA
 Biospace Lab SA Electronic Equipment/InstrumentsElectronic Technology Biospace Lab SA develops and produces imaging tools. Its products include optical imaging systems and digital autoradiography solutions. The company was founded by Georges Charpak in 1989 and is headquartered in Nesles la Vallée, France. | Electronic Equipment/Instruments | Director/Board Member Director/Board Member | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Dynacure SA
 Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
ImmunoBiology Ltd.
 ImmunoBiology Ltd. BiotechnologyHealth Technology ImmunoBiology Ltd. develops next generation of vaccines for infectious diseases. It develops vaccines that protect against pathogens by mimicking the natural immune response to infection. The firm offers ImmBioVax and ImmunoBodies vaccines. The company was founded by Camilo Colaco in 1999 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
| MORPHOSYS AG | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Humedics GmbH
 Humedics GmbH Packaged SoftwareTechnology Services Humedics GmbH operates as a research-based medtech company. It focuses on rapid and precise lover function measurement using LiMax, a breath analysis technology. The company was founded by Martin Stockman, Erwin de Bujizer, and Karsten Heyne in 2009 and is headquartered in Berlin, Germany. | Packaged Software | Director/Board Member Director/Board Member | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Founder Private Equity Investor | |
Sygnature Discovery Ltd.
 Sygnature Discovery Ltd. Pharmaceuticals: MajorHealth Technology Sygnature Discovery Ltd. engages in drug discovery activities. It specializes in target validation, hit identification, hit to lead, lead optimization, integrated drug discovery, and fragment based drug discovery. The company was founded by Simon Christopher Hirst in 2004 and is headquartered in Nottingham, United Kingdom. | Pharmaceuticals: Major | Founder Director/Board Member | |
Exosome Diagnostics, Inc.
 Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Medical/Nursing Services | Director/Board Member Chairman | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Aduro Biotech Holdings Europe BV
 Aduro Biotech Holdings Europe BV BiotechnologyHealth Technology Aduro Biotech Holdings Europe BV operates as a biopharmaceutical company specializing in immune oncology antibody discovery. The firm’s technology creates a pipeline of antibodies aiming to treat the immune system of cancer patients. Its antibody portfolio includes immune checkpoint inhibitors and novel antibody formats. The company was founded by Wiebe Olijve, Andrea van Elsas, and Hans van Eenennaam in 2011 and is headquartered in Oss, the Netherlands. | Biotechnology | Founder Corporate Officer/Principal | |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Corporate Officer/Principal Founder | |
Inventages Venture Capital Investment, Inc
 Inventages Venture Capital Investment, Inc Investment ManagersFinance Inventages Venture Capital Investment, Inc (Inventages Venture) is a venture capital firm founded in 2000 by Gunnar Carsten Weikert. The firm is headquartered in Nassau with an additional office in London. | Investment Managers | Investment Committee Member Private Equity Investor | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| IMMUNOCORE HOLDINGS PLC | Biotechnology | Founder Chief Operating Officer | |
| Harvard Business School | College/University | Corporate Officer/Principal Masters Business Admin | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
SelectX Pharmaceuticals, Inc.
 SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of Cambridge | College/University | Masters Business Admin Doctorate Degree | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| BIOTIE THERAPIES CORP | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member |
Statistiche
Distribuzione geografica
| Francia | 14 |
| Paesi Bassi | 10 |
| Svizzera | 7 |
| Regno Unito | 7 |
| Stati Uniti | 6 |
Settori
| Health Technology | 32 |
| Consumer Services | 9 |
| Finance | 6 |
| Health Services | 4 |
| Electronic Technology | 2 |
Posizioni
| Director/Board Member | 398 |
| Corporate Officer/Principal | 140 |
| Chairman | 66 |
| Independent Dir/Board Member | 58 |
| Chief Executive Officer | 57 |
Contatti più connessi
| Insiders | |
|---|---|
| Raphaël Wisniewski | 45 |
| James Noble | 39 |
| Kapil Dhingra | 39 |
| Martijn Kleijwegt | 33 |
| Jan Hendrik Egberts | 33 |
| Karen Wilson | 31 |
| Russell Greig | 31 |
| Rémi Droller | 29 |
| Nanna Liebach Lüneborg | 29 |
| Stephen DiPalma | 24 |
| Louis Joseph Nisbet | 24 |
| Guido Magni | 23 |
| Ashok Dhanrajgir | 21 |
| Robert Schier | 20 |
| Thibaut Roulon | 18 |
- Borsa valori
- Insiders
- Erik van den Berg
- Connessioni Società
